These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18217206)

  • 1. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
    Odenike OM; Larson RA; Gajria D; Dolan ME; Delaney SM; Karrison TG; Ratain MJ; Stock W
    Invest New Drugs; 2008 Jun; 26(3):233-9. PubMed ID: 18217206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
    Yen Y; Margolin K; Doroshow J; Fishman M; Johnson B; Clairmont C; Sullivan D; Sznol M
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):331-42. PubMed ID: 15148626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
    Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
    Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
    Karp JE; Giles FJ; Gojo I; Morris L; Greer J; Johnson B; Thein M; Sznol M; Low J
    Leuk Res; 2008 Jan; 32(1):71-7. PubMed ID: 17640728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
    Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
    Seiter K; Feldman EJ; Halicka HD; Traganos F; Darzynkiewicz Z; Lake D; Ahmed T
    J Clin Oncol; 1997 Jan; 15(1):44-51. PubMed ID: 8996123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
    Mackenzie MJ; Saltman D; Hirte H; Low J; Johnson C; Pond G; Moore MJ
    Invest New Drugs; 2007 Dec; 25(6):553-8. PubMed ID: 17585372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
    Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T; Hawtin R; Craig AR; Ravandi F; Maris MB; Stuart RK; Karp JE
    Haematologica; 2015 Feb; 100(2):231-7. PubMed ID: 25381131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
    Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
    J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
    Klisovic RB; Blum W; Wei X; Liu S; Liu Z; Xie Z; Vukosavljevic T; Kefauver C; Huynh L; Pang J; Zwiebel JA; Devine S; Byrd JC; Grever MR; Chan K; Marcucci G
    Clin Cancer Res; 2008 Jun; 14(12):3889-95. PubMed ID: 18559610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
    Thomas X; Cambier N; Taksin AL; Reman O; Vekhoff A; Pautas C; Leblond V; Soler-Michel P; Ecstein-Fraïssé E; Archimbaud E
    Leuk Res; 2000 Nov; 24(11):957-63. PubMed ID: 11086179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
    Choi BS; Alberti DB; Schelman WR; Kolesar JM; Thomas JP; Marnocha R; Eickhoff JC; Ivy SP; Wilding G; Holen KD
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):973-80. PubMed ID: 20127092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
    Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
    Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
    Gryn J; Conroy J; Topolsky D; Crilley P; Kahn SB; Bulova S; Weiss J; Brodsky I
    Am J Clin Oncol; 1991 Feb; 14(1):52-4. PubMed ID: 1987740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.